Female 0 6 0 6 B-gender
subject 7 14 7 14 O
considered 15 25 15 25 O
not 26 29 26 29 O
of 30 32 30 32 O
childbearing 33 45 33 45 O
potential 46 55 46 55 O
must 56 60 56 60 O
be 61 63 61 63 O
documented 64 74 64 74 O
as 75 77 75 77 O
being 78 83 78 83 O
surgically 84 94 84 94 O
sterile 95 102 95 102 O
or 103 105 103 105 O
post 106 110 106 110 O
- 110 111 110 111 O
menopausal 111 121 111 121 O
for 122 125 122 125 O
at 126 128 126 128 O
least 129 134 129 134 O
1 135 136 135 136 B-lower_bound
year 137 141 137 141 I-lower_bound

Subject 0 7 142 149 O
has 8 11 150 153 O
history 12 19 154 161 O
( 20 21 162 163 O
within 21 27 163 169 O
previous 28 36 170 178 B-upper_bound
5 37 38 179 180 I-upper_bound
years 39 44 181 186 I-upper_bound
) 44 45 186 187 O
of 46 48 188 190 O
clinically 49 59 191 201 O
significant 60 71 202 213 O
pulmonary 72 81 214 223 B-chronic_disease
hypertension 82 94 224 236 I-chronic_disease
, 94 95 236 237 O
uncontrolled 96 108 238 250 O
systemic 109 117 251 259 O
hypertension 118 130 260 272 O
or 131 133 273 275 O
hypertensive 134 146 276 288 B-chronic_disease
crisis 147 153 289 295 I-chronic_disease
, 153 154 295 296 O
symptomatic 155 166 297 308 O
heart 167 172 309 314 B-chronic_disease
failure 173 180 315 322 I-chronic_disease
, 180 181 322 323 O
cardiomyopathy 182 196 324 338 B-chronic_disease
, 196 197 338 339 O
myocardial 198 208 340 350 B-chronic_disease
infarction 209 219 351 361 I-chronic_disease
, 219 220 361 362 O
unstable 221 229 363 371 B-chronic_disease
/ 229 230 371 372 I-chronic_disease
severe 230 236 372 378 I-chronic_disease
angina 237 243 379 385 I-chronic_disease
pectoris 244 252 386 394 I-chronic_disease
, 252 253 394 395 O
cardiac 254 261 396 403 B-chronic_disease
arrhythmia 262 272 404 414 I-chronic_disease
requiring 273 282 415 424 O
medication 283 293 425 435 B-treatment
, 293 294 435 436 O
coronary 295 303 437 445 B-treatment
/ 303 304 445 446 I-treatment
peripheral 304 314 446 456 I-treatment
artery 315 321 457 463 I-treatment
bypass 322 328 464 470 I-treatment
graft 329 334 471 476 I-treatment
, 334 335 476 477 O
aneurysm 336 344 478 486 B-chronic_disease
or 345 347 487 489 O
aneurysm 348 356 490 498 B-treatment
repair 357 363 499 505 I-treatment
, 363 364 505 506 O
angioplasty 365 376 507 518 B-treatment
, 376 377 518 519 O
cerebrovascular 378 393 520 535 O
accident 394 402 536 544 O
, 402 403 544 545 O
transient 404 413 546 555 B-chronic_disease
ischemic 414 422 556 564 I-chronic_disease
attack 423 429 565 571 I-chronic_disease
or 430 432 572 574 O
the 433 436 575 578 O
left 437 441 579 583 B-clinical_variable
ventricular 442 453 584 595 I-clinical_variable
ejection 454 462 596 604 I-clinical_variable
fraction 463 471 605 613 I-clinical_variable
( 472 473 614 615 I-clinical_variable
LVEF 473 477 615 619 I-clinical_variable
) 477 478 619 620 I-clinical_variable
less 479 483 621 625 O
than 484 488 626 630 O
50 489 491 631 633 B-upper_bound
% 491 492 633 634 I-upper_bound

Subject 0 7 635 642 O
has 8 11 643 646 O
received 12 20 647 655 O
anticancer 21 31 656 666 B-treatment
therapy 32 39 667 674 I-treatment
including 40 49 675 684 O
chemotherapy 50 62 685 697 B-treatment
, 62 63 697 698 O
radiation 64 73 699 708 B-treatment
therapy 74 81 709 716 I-treatment
, 81 82 716 717 O
immunotherapy 83 96 718 731 B-treatment
, 96 97 731 732 O
biologic 98 106 733 741 B-treatment
, 106 107 741 742 O
or 108 110 743 745 O
any 111 114 746 749 O
investigational 115 130 750 765 B-treatment
therapy 131 138 766 773 I-treatment
within 139 145 774 780 O
a 146 147 781 782 O
period 148 154 783 789 O
of 155 157 790 792 O
21 158 160 793 795 B-upper_bound
days 161 165 796 800 I-upper_bound
or 166 168 801 803 O
anti 169 173 804 808 B-treatment
- 173 174 808 809 I-treatment
cancer 174 180 809 815 I-treatment
herbal 181 187 816 822 I-treatment
therapy 188 195 823 830 I-treatment
within 196 202 831 837 O
7 203 204 838 839 B-upper_bound
days 205 209 840 844 I-upper_bound
prior 210 215 845 850 I-upper_bound
to 216 218 851 853 O
Cycle 219 224 854 859 O
1 225 226 860 861 O
Day 227 230 862 865 O
1 231 232 866 867 O
of 233 235 868 870 O
ABT-165 236 243 871 878 B-treatment

Subject 0 7 879 886 O
has 8 11 887 890 O
uncontrolled 12 24 891 903 O
metastases 25 35 904 914 B-cancer
to 36 38 915 917 O
the 39 42 918 921 O
central 43 50 922 929 O
nervous 51 58 930 937 O
system 59 65 938 944 O
( 66 67 945 946 O
CNS 67 70 946 949 O
) 70 71 949 950 O

Subject 0 7 951 958 O
has 8 11 959 962 O
unresolved 12 22 963 973 O
clinically 23 33 974 984 O
significant 34 45 985 996 O
toxicities 46 56 997 1007 O
from 57 61 1008 1012 O
prior 62 67 1013 1018 B-treatment
anticancer 68 78 1019 1029 I-treatment
therapy 79 86 1030 1037 I-treatment
, 86 87 1037 1038 O
defined 88 95 1039 1046 O
as 96 98 1047 1049 O
any 99 102 1050 1053 O
Common 103 109 1054 1060 B-clinical_variable
Terminology 110 121 1061 1072 I-clinical_variable
Criteria 122 130 1073 1081 I-clinical_variable
for 131 134 1082 1085 I-clinical_variable
Adverse 135 142 1086 1093 I-clinical_variable
Events 143 149 1094 1100 I-clinical_variable
( 150 151 1101 1102 I-clinical_variable
CTCAE 151 156 1102 1107 I-clinical_variable
) 156 157 1107 1108 I-clinical_variable
Grade 158 163 1109 1114 B-lower_bound
2 164 165 1115 1116 I-lower_bound
or 166 168 1117 1119 O
higher 169 175 1120 1126 O

Subject 0 7 1127 1134 O
must 8 12 1135 1139 O
have 13 17 1140 1144 O
advanced 18 26 1145 1153 O
solid 27 32 1154 1159 B-cancer
tumor 33 38 1160 1165 I-cancer
that 39 43 1166 1170 O
is 44 46 1171 1173 O
not 47 50 1174 1177 O
amenable 51 59 1178 1186 O
to 60 62 1187 1189 O
surgical 63 71 1190 1198 B-treatment
resection 72 81 1199 1208 I-treatment
or 82 84 1209 1211 O
other 85 90 1212 1217 O
approved 91 99 1218 1226 O
therapeutic 100 111 1227 1238 O
options 112 119 1239 1246 O
that 120 124 1247 1251 O
have 125 129 1252 1256 O
demonstrated 130 142 1257 1269 O
clinical 143 151 1270 1278 O
benefit 152 159 1279 1286 O

Subject 0 7 1287 1294 O
must 8 12 1295 1299 O
have 13 17 1300 1304 O
measurable 18 28 1305 1315 O
disease 29 36 1316 1323 O
per 37 40 1324 1327 O
Response 41 49 1328 1336 O
Evaluation 50 60 1337 1347 O
Criteria 61 69 1348 1356 O
In 70 72 1357 1359 O
Solid 73 78 1360 1365 B-cancer
Tumors 79 85 1366 1372 I-cancer
( 86 87 1373 1374 O
RECIST 87 93 1374 1380 O
) 93 94 1380 1381 O
version 95 102 1382 1389 O
1.1 103 106 1390 1393 O

Subjects 0 8 1394 1402 O
in 9 11 1403 1405 O
the 12 15 1406 1409 O
combination 16 27 1410 1421 B-treatment
therapy 28 35 1422 1429 I-treatment
cohorts 36 43 1430 1437 O
must 44 48 1438 1442 O
meet 49 53 1443 1447 O
the 54 57 1448 1451 O
above 58 63 1452 1457 O
inclusion 64 73 1458 1467 O
criteria 74 82 1468 1476 O
and 83 86 1477 1480 O
be 87 89 1481 1483 O
eligible 90 98 1484 1492 O
to 99 101 1493 1495 O
receive 102 109 1496 1503 O
paclitaxel 110 120 1504 1514 B-treatment
or 121 123 1515 1517 O
FOLFIRI 124 131 1518 1525 B-treatment
per 132 135 1526 1529 O
most 136 140 1530 1534 O
current 141 148 1535 1542 O
prescribing 149 160 1543 1554 O
information 161 172 1555 1566 O
, 172 173 1566 1567 O
or 174 176 1568 1570 O
at 177 179 1571 1573 O
the 180 183 1574 1577 O
discretion 184 194 1578 1588 O
of 195 197 1589 1591 O
the 198 201 1592 1595 O
Investigator 202 214 1596 1608 O

Subjects 0 8 1609 1617 O
in 9 11 1618 1620 O
the 12 15 1621 1624 O
combination 16 27 1625 1636 B-treatment
therapy 28 35 1637 1644 I-treatment
cohorts 36 43 1645 1652 O
who 44 47 1653 1656 O
are 48 51 1657 1660 O
to 52 54 1661 1663 O
receive 55 62 1664 1671 O
ABBV-181 63 71 1672 1680 B-treatment
, 71 72 1680 1681 O
an 73 75 1682 1684 O
anti 76 80 1685 1689 B-treatment
- 80 81 1689 1690 I-treatment
PD1 81 84 1690 1693 I-treatment
antibody 85 93 1694 1702 I-treatment
, 93 94 1702 1703 O
must 95 99 1704 1708 O
also 100 104 1709 1713 O
meet 105 109 1714 1718 O
other 110 115 1719 1724 O
criteria 116 124 1725 1733 O
described 125 134 1734 1743 O
in 135 137 1744 1746 O
the 138 141 1747 1750 O
Protocol 142 150 1751 1759 O

Women 0 5 1760 1765 B-gender
of 6 8 1766 1768 O
childbearing 9 21 1769 1781 O
potential 22 31 1782 1791 O
and 32 35 1792 1795 O
men 36 39 1796 1799 O
must 40 44 1800 1804 B-contraception_consent
agree 45 50 1805 1810 I-contraception_consent
to 51 53 1811 1813 I-contraception_consent
use 54 57 1814 1817 I-contraception_consent
adequate 58 66 1818 1826 I-contraception_consent
contraception 67 80 1827 1840 I-contraception_consent

Women 0 5 1841 1846 B-gender
of 6 8 1847 1849 O
childbearing 9 21 1850 1862 O
potential 22 31 1863 1872 O
must 32 36 1873 1877 O
have 37 41 1878 1882 O
a 42 43 1883 1884 O
negative 44 52 1885 1893 B-pregnancy
serum 53 58 1894 1899 I-pregnancy
pregnancy 59 68 1900 1909 I-pregnancy
test 69 73 1910 1914 O
at 74 76 1915 1917 O
the 77 80 1918 1921 O
screening 81 90 1922 1931 O
visit 91 96 1932 1937 O
and 97 100 1938 1941 O
a 101 102 1942 1943 O
negative 103 111 1944 1952 B-pregnancy
urine 112 117 1953 1958 I-pregnancy
pregnancy 118 127 1959 1968 I-pregnancy
test 128 132 1969 1973 O
at 133 135 1974 1976 O
baseline 136 144 1977 1985 O
prior 145 150 1986 1991 O
to 151 153 1992 1994 O
the 154 157 1995 1998 O
first 158 163 1999 2004 O
dose 164 168 2005 2009 O
of 169 171 2010 2012 O
study 172 177 2013 2018 O
drug 178 182 2019 2023 O

disease 0 7 2024 2031 O
evaluable 8 17 2032 2041 O
by 18 20 2042 2044 O
assessment 21 31 2045 2055 O
of 32 34 2056 2058 O
tumor 35 40 2059 2064 B-cancer
antigens 41 49 2065 2073 O
including 50 59 2074 2083 O
but 60 63 2084 2087 O
not 64 67 2088 2091 O
limited 68 75 2092 2099 O
to 76 78 2100 2102 O
cancer 79 85 2103 2109 B-clinical_variable
antigen 86 93 2110 2117 I-clinical_variable
( 94 95 2118 2119 I-clinical_variable
CA-125 95 101 2119 2125 I-clinical_variable
) 101 102 2125 2126 I-clinical_variable
and 103 106 2127 2130 O
prostate 107 115 2131 2139 B-clinical_variable
- 115 116 2139 2140 I-clinical_variable
specific 116 124 2140 2148 I-clinical_variable
antigen 125 132 2149 2156 I-clinical_variable
( 133 134 2157 2158 I-clinical_variable
PSA 134 137 2158 2161 I-clinical_variable
) 137 138 2161 2162 I-clinical_variable

